How should hematemesis caused by lenvatinib be managed?

Management of Lenvatinib-Induced Hematemesis

Immediately discontinue lenvatinib and perform urgent upper endoscopy to identify the bleeding source, as hematemesis represents a potentially life-threatening complication requiring prompt intervention and permanent cessation of therapy in most cases.

Immediate Actions

Stop Lenvatinib Immediately

• Hematemesis is a medical emergency that mandates immediate drug discontinuation regardless of grade
• Do not attempt dose reduction as first-line management for active gastrointestinal bleeding
• The FDA label does not provide specific guidance on resuming therapy after major bleeding events, suggesting permanent discontinuation is typically warranted 1

Identify the Bleeding Source

The bleeding may originate from two distinct mechanisms:

Esophagogastric Varices (EGV) Bleeding:

• Occurs in approximately 3% of patients at 12 months, but rises to 17% in patients with high-risk varices at baseline 2
• Lenvatinib's anti-VEGF activity can precipitate variceal hemorrhage
• Patients with Child-Pugh B, portal vein thrombosis, or platelets <150,000/μL are at highest risk for having high-risk varices 2

Tumor-Related Hemorrhage:

• More common in patients with large HCCs (>90mm), where lenvatinib rapidly suppresses tumor blood flow, causing necrotic hemorrhage 3
• Can occur as early as 3 days after starting therapy 3
• May present as intratumoral or intraperitoneal bleeding that communicates with the GI tract

Diagnostic Workup

1. Urgent upper endoscopy to visualize bleeding source
2. Dynamic CT scan if endoscopy is non-diagnostic to evaluate for tumor hemorrhage 4
3. Assess hemodynamic stability and transfusion requirements
4. Check liver function (Child-Pugh score) as bleeding may worsen hepatic decompensation

Therapeutic Interventions

For Variceal Bleeding:

• Standard variceal band ligation or sclerotherapy
• Octreotide infusion
• Do NOT restart lenvatinib - the 2022 AGA guideline specifically notes that bevacizumab (with similar anti-VEGF mechanism) requires endoscopic evaluation and treatment of varices before treatment initiation 5
• Consider alternative systemic therapy without anti-VEGF activity

For Tumor-Related Hemorrhage:

• Transcatheter arterial embolization (TAE) is the treatment of choice 4
• One case report documented successful TAE followed by lenvatinib re-challenge at reduced dose (4mg/day) after confirming hemorrhage control and maintained liver function 4
• However, this represents exceptional circumstances and carries high recurrence risk

For Hepatogastric Fistula (Rare):

• Over-the-scope clip (OTSC) closure has been reported as effective 6
• Lenvatinib should be permanently discontinued as fistula formation indicates direct tumor invasion or treatment-related tissue necrosis

Critical Decision Point: Can Lenvatinib Be Resumed?

In the vast majority of cases, NO. The evidence supports:

• Variceal bleeding: Absolute contraindication to resuming lenvatinib or any anti-VEGF therapy
• Tumor hemorrhage: Only consider re-challenge if ALL of the following are met:
  • Successful TAE with complete hemorrhage control
  • Maintained Child-Pugh A liver function
  • Tumor size reduction documented on imaging
  • Patient body weight allows for significantly reduced dosing (4mg/day if <60kg) 4
  • Close monitoring with frequent imaging available

Alternative Systemic Therapy Options

After lenvatinib-induced bleeding, consider:

• Cabozantinib or regorafenib as second-line TKIs (though these also carry bleeding risk) 7
• Pembrolizumab if no portal vein invasion (avoids anti-VEGF mechanism) 5
• Ramucirumab is contraindicated (anti-VEGF mechanism, requires AFP >400 ng/mL) 5
• Atezolizumab + bevacizumab is contraindicated due to bevacizumab's anti-VEGF activity 5

Key Pitfalls to Avoid

• Never resume lenvatinib without identifying and treating the bleeding source
• Do not underestimate bleeding risk in patients with large tumors (>90mm) - consider prophylactic imaging surveillance in first weeks of therapy 3
• Baseline endoscopy should have been performed before starting lenvatinib in cirrhotic patients, per AGA guidelines 5
• Grade 5 (fatal) bleeding occurred in 3 of 17 patients who bled on lenvatinib, emphasizing the severity 2

The expert consensus emphasizes that while lenvatinib-associated adverse events can generally be managed with dose modifications 8, hematemesis represents a severe, potentially fatal complication requiring permanent discontinuation in most clinical scenarios.